Agios Pharmaceuticals (AGIO) Free Cash Flow (2012 - 2026)

Agios Pharmaceuticals (AGIO) has 15 years of Free Cash Flow data on file, last reported at -$58.5 million in Q2 2026.

• Quarterly Free Cash Flow rose 24.97% year-over-year to -$58.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$365.3 million (up 10.7% YoY) and the FY2025 annual result came in at -$377.3 million, up 3.64% from the prior year.
• Free Cash Flow climbed to -$58.5 million in Q2 2026, from -$119.7 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$58.5 million in Q2 2026 to a low of -$134.1 million in Q4 2024.
• A 5-year average of -$86.6 million and a median of -$81.3 million in 2024 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow surged 35.21% — and 2024, when it tumbled 84.45%.
• Tracing AGIO's Free Cash Flow over 5 years: stood at -$66.3 million in 2022, then decreased by 9.73% to -$72.7 million in 2023, then plunged by 84.45% to -$134.1 million in 2024, then increased by 27.44% to -$97.3 million in 2025, then surged by 39.87% to -$58.5 million in 2026.
• The last three Free Cash Flow figures came in at -$58.5 million (Q2 2026), -$119.7 million (Q1 2026), and -$97.3 million (Q4 2025), per Business Quant data.